Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

Hcv Genotype 1

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2021.03.015 ◽

2021 ◽

Vol 105 ◽

pp. 516-521

Author(s):

Anuja Pandit ◽

Nirav Bhalani ◽

B.L. Shashi Bhushan ◽

Parshottam Koradia ◽

Shweta Gargiya ◽

...

Keyword(s):

Phase Ii ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Randomized Controlled ◽

Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2021.06.030 ◽

2021 ◽

Author(s):

Anuja Pandit ◽

Nirav Bhalani ◽

B.L. Shashi Bhushan ◽

Parshottam Koradia ◽

Shweta Gargiya ◽

...

Keyword(s):

Infectious Diseases ◽

Phase Ii ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Randomized Controlled ◽

Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized, Multicenter, Open-Label Study

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2009.08.036 ◽

2010 ◽

Vol 8 (1) ◽

pp. 66-71.e1 ◽

Cited By ~ 9

Author(s):

Daniel E. Brady ◽

Dawn M. Torres ◽

Jong W. An ◽

John A. Ward ◽

Eric Lawitz ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Pegylated interferon alfa-2a (PEGASYSTM) and ribavirin combination therapy for chronic hepatitis C: A phase II open-label study

Gastroenterology ◽

10.1016/s0016-5085(00)85944-2 ◽

2000 ◽

Vol 118 (4) ◽

pp. A950 ◽

Cited By ~ 11

Author(s):

Mark S. Sulkowski ◽

Robert Reindollar ◽

J. Yu

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Combination Therapy ◽

Chronic Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

123 EFFICACY AND SAFETY OF AN INTENSIFIED REGIMEN OF PEGYLATED INTERFERON ALFA-2A PLUS RIBAVIRIN IN HCV GENOTYPE 1 NON-RESPONDERS: AN INTERIM ANALYSIS OF THE SYREN TRIAL

10.1016/s0168-8278(09)60125-2 ◽

2009 ◽

Vol 50 ◽

pp. S50

Author(s):

C. Hézode ◽

J. Foucher ◽

J.-P. Bronowicki ◽

V. Leroy ◽

A. Tran ◽

...

Keyword(s):

Interim Analysis ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Efficacy And Safety ◽

Genotype 1 ◽

Hcv Genotype ◽

Hcv Genotype 1

LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

10.1016/s0168-8278(15)30168-9 ◽

2015 ◽

Vol 62 ◽

pp. S270 ◽

Cited By ~ 44

Author(s):

P. Kwo ◽

N. Gitlin ◽

R. Nahass ◽

D. Bernstein ◽

S. Rojter ◽

...

Keyword(s):

Efficacy And Safety ◽

Genotype 1 ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Hcv Genotype ◽

Treatment Naïve ◽

Hcv Genotype 1 ◽

Chronic Hcv

1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL

10.1016/s0168-8278(13)61415-4 ◽

2013 ◽

Vol 58 ◽

pp. S569-S570 ◽

Cited By ~ 26

Author(s):

P. Ferenci ◽

T. Asselah ◽

G.R. Foster ◽

S. Zeuzem ◽

C. Sarrazin ◽

...

Keyword(s):

Pegylated Interferon ◽

Interferon Alfa ◽

Phase Iii ◽

Genotype 1 ◽

Double Blind ◽

Phase Iii Trial ◽

Treatment Naïve ◽

Hcv Genotype 1 ◽

Chronic Hcv

[572] RANDOMIZED, OPEN LABEL TRIAL COMPARING EFFICACY AND SAFETY OF PEGYLATED INTERFERON ALFA 2b VS ALFA 2b TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH NON 2/3 GENOTYPES - FINAL ANALYSIS

10.1016/s0168-8278(07)62170-9 ◽

2007 ◽

Vol 46 ◽

pp. S217-S218 ◽

Cited By ~ 1

Author(s):

H. Berak ◽

A. Kolakowska-Rzadzka ◽

M. Wasilewski ◽

J. Kowalska ◽

J.J. Stanczak ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Final Analysis ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Trial

Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study

Journal of the Neurological Sciences ◽

10.1016/j.jns.2016.01.046 ◽

2016 ◽

Vol 362 ◽

pp. 266-271 ◽

Cited By ~ 42

Author(s):

Yukio Ando ◽

Yoshiki Sekijima ◽

Konen Obayashi ◽

Taro Yamashita ◽

Mitsuharu Ueda ◽

...

Keyword(s):

Japanese Patients ◽

Familial Amyloid Polyneuropathy ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Amyloid Polyneuropathy

Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads

Gastroenterology ◽

10.1053/j.gastro.2010.08.051 ◽

2010 ◽

Vol 139 (6) ◽

pp. 1972-1983 ◽

Cited By ~ 26

Author(s):

K. Rajender Reddy ◽

Mitchell L. Shiffman ◽

Maribel Rodriguez–Torres ◽

Hugo Cheinquer ◽

Djamal Abdurakhmanov ◽

...

Keyword(s):

Pegylated Interferon ◽

Interferon Alfa ◽

High Dose ◽

Genotype 1 ◽

Hcv Genotype ◽

Viral Loads ◽

Hcv Genotype 1